Debt and Interest- Additional Information (Detail)

v3.20.1

Debt and Interest- Additional Information (Detail)										1 Months Ended					3 Months Ended	12 Months Ended
	Jul. 18, 2019 USD ($) $ / shares shares	Jul. 03, 2018 shares	Sep. 30, 2017 USD ($) $ / shares shares	Aug. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares shares	May 31, 2017 USD ($) $ / shares shares	May 01, 2017 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) $ / shares shares	Sep. 14, 2016 USD ($)	Mar. 29, 2019 USD ($) D installment $ / shares shares	Jan. 31, 2019 USD ($) shares	Mar. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2016	Feb. 13, 2014 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jul. 31, 2017 USD ($)
Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares										$ 3.47
Debt Instrument, Interest Rate, Stated Percentage																2.50%
Long-term Debt																$ 89,742,000	$ 84,406,000
Notes Payable																84,656,000	79,503,000
Debt Instrument, Term															36 months
Fair Value Adjustment of Warrants																27,000	682,000
Debt Instrument, Convertible, Terms of Conversion Feature																			(a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).
Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights									$ 1,500,000
Legal Fees									$ 25,000,000
Common shares issued for Opus debt (in shares) | shares	396,825
Common Shares Issued For Opus Debt, Issue Price | $ / shares	$ 1.26
Line Of Credit Facility, Prepayment Amount	$ 500,000
Proceeds from Convertible Debt																15,000,000	0
Debt Instrument Maturity Period Extension Description															The Company may also use the proceeds to finance its subsidiaries. The notes mature 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months
Debt Instrument Change in Periodic Interest Payment Description															Interest on the note is 8% payable quarterly during the first 24 months (or the first 30 months if the note is extended) and monthly during the last 12 months
Common shares issued (in shares) | shares		164,473
Amortization Payments, Installments | installment										18
Number of Business Days Prior Written Notice | D										10
Debt Instrument, Periodic Payment, Principal										$ 500,000
Percent of Outstanding Loan Principal Amount for Calculation of Repayment Change										4.00%
Percentage Of Amortization Loan Date										3.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate										2.00%
Line of Credit Facility, Periodic Payment										$ 250,000
Line of Credit Facility, Periodic Payment, Principal										750,000
Proceeds from Lines of Credit										$ 15,000,000
Accrued Interest Percentage										5.00%
Cash																13,000,000
Percentage of Warrants Included in Debt										5.00%
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares										288,184
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares										$ 3.47
Warrants Not Settleable in Cash, Fair Value Disclosure										$ 900,000
Development Option and Stock Purchase Agreement [Member]
Debt [Line Items]
Fair Value Adjustment of Warrants																$ 1,000,000	1,000,000
Commercial Paper [Member]
Debt [Line Items]
Debt Instrument, Face Amount															$ 21,700,000
Common Class B [Member]
Debt [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares											1,870,412
LOC Fees [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																2.00%
Letters of Credit Outstanding, Amount																$ 1,100,000
Maximum
Debt [Line Items]
Cash										13,000,000
Minimum
Debt [Line Items]
Cash										8,000,000
Israel Discount Bank Of New York [Member]
Debt [Line Items]
Current portion of note payable																$ 14,900,000	$ 14,900,000
Debt Instrument, Face Amount														$ 15,000,000
Idb Promissory Note Payable [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																2.25%
Debt Instrument, Face Amount														15,000,000
Debt Instrument, Unused Borrowing Capacity, Amount														100,000
Debt Instrument, Periodic Payment														$ 14,000,000
Opus Credit Facility [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																12.00%
Line of Credit Facility, Maximum Borrowing Capacity																$ 25,000,000
Debt Instrument, Convertible, Conversion Price | $ / shares																	$ 10.00
Warrants and Rights Outstanding																$ 9,000,000	$ 9,500,000
Maturity Date																Sep. 14, 2018
Horizon Technology Finance Corporation [Member]
Debt [Line Items]
Legal Fees										1,200,000
Line of Credit Facility, Commitment Fee Amount										200,000
Reimbursement of Legal Fees										30,000
NSC Debt [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Effective Percentage																	14.00%
Helocyte Convertible Note One [Member]
Debt [Line Items]
Debt Instrument, Fee Amount																			$ 400,000
Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights																			$ 400,000
Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights																			110.00%
Proceeds from Debt, Net of Issuance Costs																			$ 3,900,000
Helocyte Convertible Note One [Member] | Conversion One [Member]
Debt [Line Items]
Debt Instrument, Convertible, Terms of Conversion Feature																			(a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.
Helocyte Convertible Note One [Member] | Maximum
Debt [Line Items]
Debt Instrument, Face Amount																		$ 5,000,000
Helocyte Convertible Note [Member]
Debt [Line Items]
Legal Fees																			$ 100,000
Helocyte Convertible Note [Member] | Conversion One [Member]
Debt [Line Items]
Debt Instrument, Convertible, Terms of Conversion Feature													the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.
Helocyte Convertible Note [Member] | Conversion Two [Member]
Debt [Line Items]
Debt Instrument, Convertible, Terms of Conversion Feature													a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).
Caelum Convertible Note [Member]
Debt [Line Items]
Debt Instrument, Face Amount																				$ 10,000,000
Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights																	110.00%
Class of Warrant or Right Exercise Price Description																		the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company
Debt Conversion, Description																		The notes convert upon a qualified financing in which Caelum raises gross proceeds of at least $10 million as follows: the lesser of (a) a discount to the price per common share being paid in the Sale of the Company equal to 20% or (b) a conversion price per share based on a pre-sale valuation of $75,000,000 divided by the number of common shares outstanding at that time assuming the hypothetical conversion or exercise of any convertible securities, options, warrants and other rights to acquire common shares of the Company
Percentage Of Placement Agent Fee																		10.00%
Debt Instrument Issuance Percentage of Commission																		10.00%
Proceeds from Convertible Debt																	$ 9,900,000
Payments of Financing Costs																	900,000
NSC 2017 Note [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								8.00%				8.00%
Debt Instrument, Face Amount								$ 3,250,000				$ 3,250,000
Debt Instrument, Maturity Date, Description												Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.
Paid-in-kind Interest Percentage								7.00%				7.00%
Line of Credit Facility, Current Borrowing Capacity								$ 50,000,000				$ 50,000,000
Percentage Of Placement Agent Fee												10.00%
Warrant on Sale Price of Note Percentage								10.00%				10.00%
NSC 2017 Note [Member] | First Closing [Member]
Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares								87,946				87,946
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 3.70				$ 3.70
Cash proceeds from 2008 Senior Convertible Notes								$ 3,200,000
Proceeds from Fees Received								$ 300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 3.70				$ 3.70
NSC 2017 Note [Member] | Secoud Closing [Member]
Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares							234,438
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 3.65
Cash proceeds from 2008 Senior Convertible Notes							$ 8,600,000
Proceeds from Fees Received							$ 900,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 3.65
NSC 2017 Note [Member] | Third Closing [Member]
Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						147,806
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 3.61
Cash proceeds from 2008 Senior Convertible Notes						$ 5,300,000
Proceeds from Fees Received						$ 500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 3.61
NSC 2017 Note [Member] | Fourth Closing [Member]
Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					38,315
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 4.75
Cash proceeds from 2008 Senior Convertible Notes					$ 1,800,000
Proceeds from Fees Received					$ 200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 4.75
NSC 2017 Note [Member] | Fifth Closing [Member]
Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				63,526
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 4.75
Cash proceeds from 2008 Senior Convertible Notes				$ 3,000,000
Proceeds from Fees Received				$ 300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 4.75
NSC 2017 Note [Member] | Sixth Closing [Member]
Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			144,149
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 4.42
Cash proceeds from 2008 Senior Convertible Notes			$ 6,400,000
Proceeds from Fees Received			$ 600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 4.42
NSC 2017 Note [Member] | Maximum
Debt [Line Items]
Debt Instrument, Face Amount								$ 40,000,000				$ 40,000,000
Venture Notes One [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																8.00%
Long-term Debt																$ 6,517,000	6,517,000
DOSPA [Member]
Debt [Line Items]
Debt Instrument, Face Amount																	$ 9,900,000
Sale of Stock, Consideration Received on Transaction											$ 30,000,000
Sale of Stock Percentage of Shares Transferred on Transaction											19.90%
Mustang Two Thousand Nineteen Venture Debt [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																2.50%
Line of Credit Facility, Maximum Borrowing Capacity										15,000,000
Line of Credit Facility, Current Borrowing Capacity										20,000,000
Line Of Credit Facility, Prepayment Amount										$ 5,000,000
LIBOR Rate [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																9.00%
Debt Instrument, Basis Spread on Variable Rate										9.00%
N S C [Member] | Venture Notes One [Member]
Debt [Line Items]
Warrant on Sale Price of Note Percentage																25.00%
Payments of Financing Costs															$ 1,700,000
Class Of Warrant Or Right Expiration Period																10 years
Aevitas Therapeutics Inc [Member] | Venture Notes One [Member]
Debt [Line Items]
Cash proceeds from 2008 Senior Convertible Notes																$ 3,800,000
Tamid Bio Inc [Member] | Venture Notes One [Member]
Debt [Line Items]
Cash proceeds from 2008 Senior Convertible Notes																1,600,000
Cellvation [Member] | Venture Notes One [Member]
Debt [Line Items]
Cash proceeds from 2008 Senior Convertible Notes																2,200,000
Cyprium [Member] | Venture Notes One [Member]
Debt [Line Items]
Cash proceeds from 2008 Senior Convertible Notes																$ 2,000,000